Home » Oculus Announces 510(k) Clearance of Microcyn Technology
Oculus Announces 510(k) Clearance of Microcyn Technology
May 10, 2005
Hoji Alimi, founder and president of Oculus Innovative Sciences, announced that the company has received its first 510(k) clearance from the FDA to market Dermacyn Wound Care, formulated with Microcyn Technology, as a medical device for moistening, lubricating and debriding of acute and traumatic wounds and burns. Microcyn Technology is a super-oxidized, pH-neutral solution that is ready for use with no dilution or mixing, and requires no special handling or disposal.
Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050509005577&newsLang=en)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct